Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0756 -0.0025 (-3.20%)
Streaming Delayed Price Updated: 3:01 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmather Hldgs Ltd

< Previous 1 2 3 4 Next >
News headline image
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher Provides Business Highlights And Releases Audited Annual Financials ↗
PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.  
Via Benzinga
News headline image
PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher Presents Positive Data On Ketamine For Treatment Of Dyskinesia In Parkinson's Disease ↗
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, announced Friday that the Phase 1/2 clinical study of ketamine in the treatment of levodopa-induced... 
Via Benzinga
News headline image
Intradermal Ketamine Patch Completes Pre-Clinical Phase, Advances To Clinical Studies ↗
PharmaTher Holdings (OTCQB: PHRRF), the biopharma company developing novel uses and delivery forms of ketamine for mental health treatments, has completed an IND-enabling pharmacokinetic and... 
Via Benzinga
News headline image
PharmaTher Receives Notice Of Allowance For U.S. Patent Covering Ketamine For Parkinson's And Motor Disorders Treatment ↗
Ketamine pharmaceuticals provider PharmaTher Holdings Ltd. (OTCQB: PHRRF) has been granted a Notice of Allowance by the U.S. 
Via Benzinga
News headline image
PharmaTher's Preclinical Trial For Ketamine Micro-Needle Patch Shows Positive Results For Dosing ↗
Ketamine-producer PharmaTher Holdings Ltd. (OTCQB: PHRRF) has successfully completed research evaluating its patented hydrogel-forming microneedle patch, PHARMAPATCH, to deliver ketamine and KETABET... 
Via Benzinga
News headline image
These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry ↗
In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its... 
Via Benzinga
News headline image
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO ↗
PharmaTher Holdings Ltd. (OTC: PHRRF) continues on its path to becoming the leader in specialty ketamine products. 
Via Benzinga
News headline image
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs ↗
Psychedelics policy action took center stage this week. 
Via Benzinga
News headline image
Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process ↗
The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process. 
Via Benzinga
News headline image
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward ↗
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions. 
Via Benzinga
News headline image
Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy ↗
Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022. 
Via Benzinga
News headline image
Ketamine Could Help Treat Parkinson's Disease, Study Finds ↗
PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced positive results from a clinical study of ketamine for the treatment of ... 
Via Benzinga
News headline image
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022 ↗
This article was originally published on Micr... 
Via Benzinga
News headline image
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment ↗
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced... 
Via Benzinga
News headline image
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval ↗
Detroit Decriminalizes Psychedelics 
Via Benzinga
News headline image
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program ↗
The Week In Psychedelics 
Via Benzinga
News headline image
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction ↗
The Week In Psychedelics: 
Via Benzinga
News headline image
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗
The Week In Psychedelics 
Via Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
Via FinancialNewsMedia
News headline image
These OTC Securities Had the Most Trading Activity in June ↗
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... 
Via Benzinga
Topics Cannabis
News headline image
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
News headline image
How To Invest In "Magic Mushrooms" (Psychedelics) ↗
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
News headline image
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies ↗
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
News headline image
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More ↗
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
News headline image
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research ↗
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ: 
Via Benzinga
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading ↗
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ... 
Via Benzinga
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.